(34 days)
This document does not contain K/DEN numbers.
Not Found
No
The summary describes a quantitative in vitro diagnostic assay for glycated proteins, which is a standard biochemical test. There is no mention of AI, ML, image processing, or any other technology typically associated with AI/ML in medical devices. The performance studies focus on standard analytical metrics like correlation, linearity, and precision.
No.
This device is an in vitro diagnostic (IVD) device used for the quantitative determination of glycated proteins, which provides information about mean blood glucose levels. It is used for diagnostic purposes, not for treating or preventing disease.
Yes
The "Intended Use / Indications for Use" section explicitly states "For In Vitro Diagnostic Use." Additionally, the device is described as a "quantitative method for the detection of glycated proteins in serum and plasma," with the measurement being "representative of the mean blood glucose levels," which are all characteristics of a diagnostic device.
No
The device description explicitly states it consists of Reagent, Calibrator, Low Control, and High Control, which are physical components, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states:
- "For the quantitative determination of glycated proteins." This indicates a diagnostic purpose.
- "For In Vitro Diagnostic Use." This is a direct statement confirming its IVD classification.
Furthermore, the description of the components (Reagent, Calibrator, Controls) and their intended use in a clinical laboratory setting for measuring a biological marker (glycated proteins) in patient samples (serum and plasma) aligns perfectly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
GlyPro Reagent
For the quantitative determination of glycated proteins.
Measurement of glycated serum protein is representative of the mean blood glucose levels over the preceding 2-3 weeks
For In Vitro Diagnostic Use.
GlyPro Callbrator
For calibration of the GlyPro™ assay.
For In Vitro Diagnostic Use.
GlyPro Low and High Controls
To monitor the performance of the GlyPro assay. For In Vitro Diagnostic Use.
Product codes
81 LCP
Device Description
The Genzyme GlyPro Assay System (consisting of Reagent, Calibrator, Low Control and High Control) is a quantitative method for the detection of glycated proteins in serum and plasma.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Clinical laboratory setting
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative Performance Studies: A Comparative performance study was conducted using the Genzyme GlyPro Reagent, and predicate method (Roche Unimate Fructosamine). The slope, intercept, correlation coefficient, and sample range for these comparisons are provided below.
GlyPro vs. Furosine n= 61: Slope 15.25, Intercept (µmol/L) 0.41, Correlation Coefficient (r) 0.9881, Sample Range 7.40 - 48.58 (peak area x 104)
GlyPro vs. Roche n= 61: Slope 1.33, Intercept (µmol/L) -127.45, Correlation Coefficient (r) 0.9915, Sample Range 169.0 - 675.5 (µmol/L)
The Genzyme method yielded acceptable correlation with the predicate and Furosine methods in samples across the usable range of the product.
Linearity: Linearity studies demonstrated that the GlyPro assay is linear up to 1734 umol/L.
Precision:
- Within-Run: Each serum pool was tested 20 times in one batch using the GlyPro Reagent assay. The mean, standard deviation (SD) and coefficient of variation (%CV) was calculated for each serum pool.
- Low: n=20, Sample Range (µmol/L) 179-182, Mean (µmol/L) 180.7, SD (µmol/L) 1.34, %CV 0.74
- Medium: n=20, Sample Range (µmol/L) 403-408, Mean (µmol/L) 405.3, SD (µmol/L) 1.25, %CV 0.31
- High: n=20, Sample Range (µmol/L) 656-670, Mean (µmol/L) 663.6, SD (µmol/L) 4.55, %CV 0.69
The GlyPro assay yielded excellent within-run precision with CVs of ≤ 1.0% and SD values of ≤ 5 µmo/L.
- Between-Run: Each serum pool was tested twice per day, for ten days using the GlyPro assay for a total of 20 determinations. The mean, SD and %CV were calculated for each pool.
- Low: n=20, Sample Range (umol/L) 175 - 185, Mean (umol/L) 179.6, SD (umol/L) 2.99, %CV 1.66
- Medium: n=20, Sample Range (umol/L) 396 - 408, Mean (umol/L) 402.3, SD (umol/L) 3.17, %CV 0.79
- High: n=20, Sample Range (umol/L) 644 - 665, Mean (umol/L) 654.6, SD (umol/L) 5.73, %CV 0.88
The GlyPro assay yielded excellent between-run precision with CVs ≤ 2.0% and SDs ≤ 6 µmol/L.
Interference Studies: The effects of interfering substances was evaluated by adding varying levels of potential interferents to a specimen pool. These determined that triglyceride (Avian), ascorbic acid, bilirubin, hemoglobin, uric acid and glucose did not interfere with the performance of the Genzyme GlyPro assay at the levels up to and including those indicated below.
- Triglyceride (Avian): 750 mg/dL
- Ascorbic Acid: 8 mg/dL
- Bilirubin: 29 mg/dL
- Hemoglobin: 200 mg/dL
- Uric Acid: 33 mg/dL
- Glucose: 1800 mg/dL
Additionally, a drug interference study was performed. Only the drugs listed below were found to interfere significantly at concentrations less than the therapeutic dose: - Dobesilate: 10 mg/L
- Gentisic Acid: 25 mg/L
- Methampyrone: 100 mg/L
Serum vs. Plasma: Matched sets of serum and EDTA plasma specimens were tested with the GlyPro Reagent. Data demonstrate that EDTA plasma results are 6% lower than serum results. It is preferable that the same sample type be used for all comparative analyses of the same patient.
Reference Range: The reference range was calculated according to NCCLS C28-A using non-parametric analysis. The 95% 122 - 238 umol/L reference range of the assay is.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Roche Unimate Fructosamine
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.7470 Glycosylated hemoglobin assay.
(a)
Identification. A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.(b)
Classification. Class II (performance standards).
0
510(k) PREMARKET NOTIFICATION
GlvPro™ Reagent. Low Control and High Control October 5, 1998
NOV 25 1998
ATTACHMENT 1
510(k) Summary Of Safety and Effectiveness Information Upon Which An Equivalence Determination Could be Made
| Trade or Proprietary Name: | GlyPro™ Reagent
GlyPro™ Calibrator
GlyPro™ Low Control
GlyPro™ High Control |
|----------------------------|--------------------------------------------------------------------------------------|
| Common or Usual Name: | Assay, Glycosylated Hemoglobin |
| Classification Name: | Glycosylated Hemoglobin Assay |
| Manufacturer: | Genzyme Diagnostics
One Kendall Square
Cambridge, MA 02139-1562 |
| Contact Person: | Barbara Pizza, Manager, Regulatory Affairs, (617) 252-7953 |
The use of the Genzyme GlyPro™ Reagent assay in the clinical laboratory setting is substantially equivalent to a currently marketed method for Fructosamine for the management of Diabetes.
The Genzyme GlyPro Assay System (consisting of Reagent, Calibrator, Low Control and High Control) is a quantitative method for the detection of glycated proteins in serum and plasma.
PERFORMANCE STUDIES
Comparative Performance Studies
A Comparative performance study was conducted using the Genzyme GlyPro Reagent, and predicate method (Roche Unimate Fructosamine).
The slope, intercept, correlation coefficient, and sample range for these comparisons are provided below.
1
| | GlyPro vs. Furosine
n= 61 | GlyPro vs. Roche
n= 61 |
|-----------------------------|-----------------------------------|---------------------------|
| Slope | 15.25 | 1.33 |
| Intercept (µmol/L) | 0.41 | -127.45 |
| Correlation Coefficient (r) | 0.9881 | 0.9915 |
| Sample Range | 7.40 - 48.58
(peak area x 104) | 169.0 - 675.5 (µmol/L) |
The Genzyme method yielded acceptable correlation with the predicate and Furosine methods in samples across the usable range of the product.
Linearity
Linearity studies demonstrated that the GlyPro assay is linear up to 1734 umol/L.
Precision
Both within-run and between-run studies were performed. Testing was done using frozen serum pools at three target levels of glycated serum protein for within-run precision and between-run.
Within-Run
Each serum pool was tested 20 times in one batch using the GlyPro Reagent assay . The mean, standard deviation (SD) and coefficient of variation (%CV) was calculated for each serum pool.
| Low | Medium | High | |
|---|---|---|---|
| n | 20 | 20 | 20 |
| Sample Range (µmol/L) | 179-182 | 403-408 | 656-670 |
| Mean (µmol/L) | 180.7 | 405.3 | 663.6 |
| SD (µmol/L) | 1.34 | 1.25 | 4.55 |
| %CV | 0.74 | 0.31 | 0.69 |
The GlyPro assay yielded excellent within-run precision with CVs of ≤ 1.0% and SD values of ≤ 5 µmo/L.
Between-Run
Each serum pool was tested twice per day, for ten days using the GlyPro assay for a total of 20 determinations. The mean, SD and %CV were calculated for each pool as follows:
2
| Low | Medium | High | |
|---|---|---|---|
| n | 20 | 20 | 20 |
| Sample Range (umol/L) | 175 - 185 | 396 - 408 | 644 - 665 |
| Mean (umol/L) | 179.6 | 402.3 | 654.6 |
| SD (umol/L) | 2.99 | 3.17 | 5.73 |
| %CV | 1.66 | 0.79 | 0.88 |
The GlyPro assay yielded excellent between-run precision with CVs ≤ 2.0% and SDs ≤ 6 µmol/L.
Interference Studies
The effects of interfering substances was evaluated by adding varying levels of potential interferents to a specimen pool. These determined that triglyceride (Avian), ascorbic acid, bilirubin, hemoglobin, uric acid and glucose did not interfere with the performance of the Genzyme GlyPro assay at the levels up to and including those indicated below.
| Interfering Substance | Concentration* |
|---|---|
| Triglyceride (Avian) | 750 mg/dL |
| Ascorbic Acid | 8 mg/dL |
| Bilirubin | 29 mg/dL |
| Hemoglobin | 200 mg/dL |
| Uric Acid | 33 mg/dL |
| Glucose | 1800 mg/dL |
*Different analyzer applications will have different interferences.
Additionally, a drug interference study was performed. Only the drugs listed below were found to interfere significantly at concentrations less than the therapeutic dose:
| Drug | Interfering concentration |
|---|---|
| Dobesilate | 10 mg/L |
| Gentisic Acid | 25 mg/L |
| Methampyrone | 100 mg/L |
Serum vs. Plasma
Matched sets of serum and EDTA plasma specimens were tested with the GlyPro Reagent. Data demonstrate that EDTA plasma results are 6% lower than serum results. It is preferable that the same sample type be used for all comparative analyses of the same patient.
3
Reference Range
The reference range was calculated according to NCCLS C28-A using non-parametric analysis. The 95% 122 - 238 umol/L reference range of the assay is:
Conclusion
Based on the results of the studies described above, the Genzyme GlyPro Reagent assay is substantially equivalent in performance to the predicate, Roche Unimate Fructosamine, a commercially marketed method for quantifying glycated proteins in serum and plasma.
In lieu of a 510(k) statement under 513(i) of the Act, this information is provided as a 510(k) summary for disclosure to any other persons/companies without the specific written authorization from Genzyme Corporation.
4
Image /page/4/Picture/2 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the seal is an abstract image of a caduceus, a symbol often associated with medicine and healthcare. The caduceus is depicted with three intertwined strands and a stylized head at the top.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV 2 5 1998
Ms. Barbara Pizza Manager, Regulatory Affairs GENZYME CORPORATION One Kendall Square Cambridge, MA 02139
Re: K983726
Trade Name: GlyPro™ Reagent, GlyPro™ Calibrator, GlyPro™ Low Control, GlyPro™ High Control Requlatory Class: II Product Code: 81 LCP Dated: October 20, 1998 Received: October 22, 1998
Dear Ms. Pizza:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Druq Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in In addition, FDA may publish further regulatory action. announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
510(k) PREMARKET NOTIFICATION
Genzyme Corporation One Kendall Square Cambridge, MA 02139
GlyPro™ Reagent, Calibrator, Controls Reference No. K983726 Confidential
November 20, 1998
Page_1 of____________________________________________________________________________________________________________________________________________________________________________
K983726 SIO(K) NUMBER (IF KNOWN):
GlyPro™ Reagent, Callbrator, Controls DEVICE NAME:
INDICATIONS FOR USE:
GlyPro Reagent
l
For the quantitative determination of glycated proteins.
Measurement of glycated serum protein is representative of the mean blood glucose levels over the preceding 2-3 weeks
For In Vitro Diagnostic Use.
GlyPro Callbrator
For calibration of the GlyPro™ assay.
For In Vitro Diagnostic Use.
GlyPro Low and High Controls
To monitor the performance of the GlyPro assay. For In Vitro Diagnostic Use.
Avonsty
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter-Use
(Optional Format 1-2-96